

PCT/1805/745

PA 1285852

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 24, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/599,331

FILING DATE: August 05, 2004

REC'D 04 APR 2004

WIPO PCT

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



N. Woodson
N. WOODSON
Certifying Officer

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. ER 875613817 US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Kwan Po Francis		Wong Chi		Kowloon, Hong Kong Kowloon, Hong Kong	
Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Methods for Preventing Deterioration in Mass and/or Increasing Mass in Lymphatic Organs					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		23557			
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		25	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		3	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input type="checkbox"/> CD(s), Number			
		<input type="checkbox"/> Other (specify)		Certificate of Mailing by Express Mail	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 19-0065				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				\$80.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

Date August 5, 2004

TYPED or PRINTED NAME Margaret Efron

REGISTRATION NO. 47.545

(if appropriate)

TELEPHONE (352) 375-8100

Docket Number: OBI-103CP

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Provisional Patent Application
Docket No. OBI-103CP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. : OBI-103CP
Applicant(s) : Kwan Po Wong and Francis Chi
For : Methods for Preventing Deterioration in Mass and/or Increasing Mass in
Lymphatic Organs


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 C.F.R. §1.10)

Express Mail No. **ER875613817US** Date of Deposit: August 5, 2004

I hereby certify that the items listed on the attached Provisional Application and Cover Sheet, with copies as required for authorization for use of Deposit Account No.19-0065, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and are addressed to: Mail Stop PROVISIONAL PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lindsay Johnson
Typed/Printed Name of Person Mailing Paper


Signature

DESCRIPTIONMETHODS FOR PREVENTING DETERIORATION IN MASS
AND/OR INCREASING MASS IN LYMPHATIC ORGANS

5

Background of the Invention

The immune system is a highly complex, biological system that requires the cooperation of a large number of different cell types. The systems of the body that make up the immune system network are variously categorized as belonging to the hematopoietic system, the reticuloendothelial or phagocytic system, and the lymphatic system.

The lymphatic system is made up of lymphocytes, and is responsible for the overall regulation of the immune system and for the production of antibodies. Lymphocytes can be concentrated within organs or can form a more or less diffuse lymphoid tissue, both of which collectively constitute the lymphatic system. Primary lymphatic organs (also known as "central tissues"), such as the thymus and bone marrow, are the major sites of lymphopoiesis. Secondary lymphoid organs and tissues (also known as "peripheral tissues"), such as the spleen, lymph nodes, lymphoid formations associated with the mucosae (or "MALT" for mucosal associated lymphoid tissue), Peyer's patches, and palatine tonsils, are those sites within which lymphocytes can interact with one another or with a foreign substance or organism (also known as an "antigen"). In addition, a large number of lymphocytes can be found in the mucosa of the stomach, of the small intestine, of the colon, of the bronchi and of various other organs.

Although there are many classes of lymphocytes, T-lymphocytes (or T-cells) and B-lymphocytes (or B-cells) make up a majority of the lymphocyte population. B-lymphocytes are generally responsible for the production of antibodies (immunoglobulin) in response to a challenge by a particular antigen. T-lymphocytes are responsible for the general regulation of the immune system and are also the principal mediators in cell-mediated immune responses.

All lymphocytes are ultimately derived from stem cells in bone marrow. These lymphocyte precursors are dispersed into the blood where they course through many organs. However, critical events take place in the thymus that imprint the lymphocytes with special functions and that regulate lymphocyte development into either T- or B-lymphocytes.

B-lymphocytes have significantly different biological functions from those of T-lymphocytes. While B-lymphocytes are involved in the final pathway of the humoral immune system (antibody production), T-lymphocytes encompass several subtypes of cells that play roles varying from immune system regulation to execution of the cytotoxic immune system. In addition to being responsible for antibody production, B-cells have some ability to engulf and "present" the antigen to a specific T-cell (also known as a T-helper cell) to stimulate the immune system.

T-lymphocytes are formed in the thymus from lymphoblasts that have left the bone marrow. The thymic cortex is rich in lymphocytes of all sizes. These thymocytes are not morphologically distinguishable from lymphocytes in other tissues, but they are immature and antigenically identifiable by the presence of several cell surface antigens including the T antigen, which is a distinctive surface marker antigen that separates the T-lymphocyte from the B-lymphocyte.

The spleen, which is located under the left side of the diaphragm, receives blood from an artery off of the aorta. Nests of B-lymphocytes surround the blood vessels of the spleen. After passing through this intricate meshwork of tiny blood vessels, the blood continues to the liver.

The spleen serves at least four major physiologic functions. First, as part of the peripheral immune system, it clears the blood of microorganisms and particulate antigens and/or generates antigens to foreign substances. Second, it sequesters and removes excess, old and/or abnormal blood cells. Third, its vasculature is involved in the regulation of portal blood flow. Finally, it engages in hematopoiesis during development or when the bone marrow alone cannot produce sufficient blood cells.

The spleen consists of red pulp, which contains blood-filled sinuses and pulp cords lined by reticuloendothelial cells, and of white pulp, which is arranged around a

central arteriole. The surrounding periarteriolar lymphoid sheath (PALS) contains both T- and B-lymphocyte areas. The T-lymphocyte area lies adjacent to the arteriole and consists of small, densely packed lymphocytes. Outside of the T-cell area is the follicular zone, which contains B-lymphocytes, and germinal centers, which are made up of B-cells and macrophages. The white pulp is surrounded by a marginal zone containing specialized, antigen-presenting macrophages and B-cells.

The intestine is the organ richest in lymphocyte cells, which circulate in blood vessels and lymph vessels, or which collect and multiply in the small intestine (major lymphocytic tissues in the small intestine known as Peyer's patches). These lymphocytic cells are a component of MALT, which is subdivided into gut-associated lymphoid tissues ("GALT") situated in the intestine and into bronchial-associated lymphoid tissues ("BALT") situated in the bronchi, and which has analogies with skin-associated lymphoid tissues ("SALT") situated in the skin. GALT and BALT are interdependent and act in synergism to ensure the immune defense of the mucosa and to contribute towards the defense of the organism as a whole.

Unlike the lymph node, the Peyer's patches (PP) does not have a capsule of afferent lymphatics. The epithelium over the PP lacks the crypts and villi of normal gut epithelium and is referred to as follicle-associated epithelium (FAE) containing cells called M cells. These are the major route of antigen transfer into the PP, and allow for direct sampling of antigen from the gut lumen by pinocytosis. Antigen is transported from the epithelium and presented to immunocompetent B-cells, macrophages and dendritic cells in the underlying area. The colon has similar lymphoid arrangements called the lymphoid follicles. Lymphoid follicles are not identical to PP, but also have specialized epithelium containing M cells, and probably function as antigen presenting sites.

Underneath the epithelium there is a tissue called the lamina propria, which forms the core of the villus and is densely infiltrated with lymphocytes bearing homing receptors, which selectively bind to the mucosal lymphoid high endothelium. B-cells comprise about 50% of the lymphocytes in the lamina propria of the gut, whereas the other half of lymphocytes are T-cells. In the normal intestine, most of the B-cells in the

lamina propria are IgA+, although IgM-, IgG- and IgD-expressing cells are also found. Most of the immunoglobulin secreted into the intestine is IgA, and half of that is IgA-2, in contrast to the lymph nodes where most of the secreted IgA is of the IgA-1 isotype. The abundance of IgA antibodies is considered crucial for immunological homeostasis within the lamina propria. IgA antibodies lack potent effector functions such as complement activation, and may therefore block non-specific biological amplification mechanisms triggered by locally produced or serum-derived IgG antibodies.

Anatomically, the thymus is situated in the anterior thoracic cage over the heart. A bilobed organ, the thymus is composed of epithelial cells and other structural cells that divide it into a complex assembly of continuous lobes, each of which is heavily laden with lymphocytes. The thymus is nourished and drained by the vascular and lymphatic systems, and innervated by the autonomic nerves.

Embryologically, the thymus emerges from the third and fourth branchial pouches. The human thymus is a fully developed organ at birth and weighs 15 to 20 grams. By puberty it weighs 40 grams, after which it atrophies or involutes, becoming less significant structurally and functionally. Atrophy of the thymus with age is a characteristic of all species, which is associated with aging, and the cessation of growth. The incidence of age related diseases increases as the thymus shrinks and thymus-dependent immunity decreases. This age-associated decrease in thymic weight, called "involution," is accompanied by changes in the thymic structure and a general decline in thymic function.

Thus, the thymus is normally active only during the early years of life. During those years, the thymus supplies T-lymphocytes that will serve the animal for the rest of its life. In certain diseases, such as rheumatoid arthritis, the thymus may regain some activity during adult life. This demonstrates that the adult thymus retains the capacity to function and that involution is not necessarily permanent. At least partial function might be restored if appropriate agents are available.

Transient involution of the thymus may also occur as a consequence of a stress or infection. Thymic involution may be controlled hormonally; castration slows involution while injection of corticosteroid hormones accelerates involution. Numerous studies

have demonstrated that the thymic involution associated with increasing age parallels a reduction of T-lymphocyte-mediated immunity and increased incidence of diseases associated with aging. Many diseases and treatments can accelerate involution of the thymus; virtually none are known to enhance growth of the thymus or reverse involution.

5 Studies have demonstrated that the thymus in the normal adult is slowly involuting, which affects thymus function. Moreover, in the normal adult, killed T-lymphocytes cannot be replaced, thus leaving the patient vulnerable to subsequent infections. Especially striking are recent studies of the thymuses of deceased AIDS patients ranging in age from 10 months to 42 years. AIDS victims have profound thymic
10 involution; much more extensive than in age-matched patients who died of other causes.

Another area where there is a need to re-establish the lymphatic system, and also the hematopoietic system, is in total body irradiation for treatment of leukemia. When a patient undergoes high dose total body irradiation, the entire immune system is compromised. The usual treatment after the irradiation is to perform a bone marrow
15 transplant with marrow from a close relative. If the transplant is successful, the new marrow will produce new cells, thereby restoring both red blood cells and white blood cells to the body. However, this is a dangerous treatment that is successful in only a fraction of the cases. Localized radiation of tumors and several types of chemotherapy also produce suppression of T-cell mediated immunity.

20 In addition, there is a need for effective treatments for stress, which may be also be useful in augmenting and/or preventing any decrease in lymphatic organ function. Stress is defined as a physical, chemical, or emotional factor that causes bodily or mental tension and may be a factor in disease causation (see Merriam-Webster Medical Dictionary, Merriam-Webster, Inc. (2002)). Mental tension (or emotional stress) can
25 occur when situations are considered difficult or unmanageable. Psychological stresses induced by restraint, confinement, sudden exposure to danger, shock and the like translate into physical stresses affecting one or more organs of the body. Bodily tension (or physical stress) refers to a physiological reaction of the body to any of the factors cited above. Physical stress such as exposure to heat or cold, injury including surgical
30 injury, over-exertion and the like, result in abnormal functioning of body organs. Stress

is now recognized as a major detrimental factor in many diseases such as cardiovascular disease, cancer, and immunological dysfunction (see Kodama, M. *et al.*, "Does surgical stress cause tumor metastasis?" *Anticancer Res*, 12(5):1603-16 (1992); Habra, M. *et al.*, "Type D personality is related to cardiovascular and neuroendocrine reactivity to acute stress," *J Psychosom Res.*, 55(3):235-45 (2003); and Uchino, B. *et al.*, "Individual differences in cardiac sympathetic control predict endocrine and immune responses to acute psychological stress," *J Pers Soc Psychol.*, 69(4):736-43 (1995)).

Physiologic responses to all stresses are the same; only the intensity of the response and whether or not any given response will be evoked are highly individual. Acute stress, such as that resulting from a trauma, robbery, or loud noise produces a physiologic response that quickly disappears, after which the body returns to its normal, unstressed state. Chronic stress, caused for example by a divorce, an unpleasant boss, or lack of money, is more insidious; the physiologic response endures and the body fails to return to its normal, baseline state. Studies have shown that being in a continuous state of stress can lead to tissue changes (*i.e.*, adrenal hypertrophy, gastrointestinal ulceration, thymic and lymphoid atrophy) and may even culminate in death (Selye HA, The Stress of Life, New York, NY: McGraw-Hill (1976)).

A variety of physiological functions occur as a result of stress, including changes in immune function, hormone levels, enzymes, and gastrointestinal function. In particular, "stress hormones" such as norepinephrine, epinephrine, and cortisol are released into the circulation to prepare the body for a "flight or fight" response after a stressful event. The effects of stress on a mammal normally manifest themselves in an increase in body temperature, along with a change in hemodynamic parameters, including an increase in heart rate and an increase in blood pressure. For patients already suffering from elevated blood pressure (*i.e.*, hypertension), the effects of stress can be particularly dangerous since hypertension is a major risk factor for cardiovascular disease.

Stress and emotions associated with stress are important risk factors in the development of cardiovascular problems (Kawachi, I. *et al.*, "Symptoms of anxiety and risk of coronary heart disease," The Normative Aging Study. *Circulation*, 90:2225-2229 (1994)). For example, when comparing men reporting the lowest levels of worry (an

emotion associated with stress) against men reporting the highest level of worry, men with highest level of worry had a multivariate adjusted relative risk of 2.41 (95% confidence interval: 1.40-4.13) for nonfatal myocardial infarction and of 1.48 (95% confidence interval: 0.99-2.20) for total coronary heart disease (nonfatal myocardial infarction and fatal coronary heart disease). See Kubzansky, LD *et al.*, "Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study," *Circulation*, 95:818-824 (1997).

Moreover, research indicates that a bout of acute stress in virtually any form will cause, at the very least, a temporary decrease in functioning of the immune system. Whereas in the case of chronic stress, a continued decline in immune system function is often observed (Irwin, M. *et al.*, "Reduction of immune function in life stress and depression," *Biol Psychiatry*, 27:22-30 (1990)). Specifically, stress has a detrimental effect on the ability to maintain optimal levels of natural killer (NK) cell cytotoxic activity (Irwin, M. *et al.*, "Plasma cortisol and natural killer cell activity during bereavement," *Biol Psychiatry*, 24:173-178 (1988); Sieber, W.J. *et al.*, "Modulation of human natural killer cell activity by exposure to uncontrollable stress," *Brain Behav Immun*, 6:141-156 (1992)), which plays a vital role in immune system surveillance against viral-infected and cancer cells.

Stress also has a significant influence on the balance of intestinal microflora (see Huis Veld JH, "Gastrointestinal flora and health in man and animal," *Tijdschr Diergeneeskde*, 116:232-239 (1991) [article in Dutch]). Research has demonstrated that, "the composition of the [intestinal micro]flora was not significantly affected by drastic changes in diet, but statistically significant shifts in the proportions of some species [of microflora] were noted in individuals under conditions of anger or fear stress." See Moore, WE *et al.*, "Some current concepts in intestinal bacteriology," *Am J Clin Nutr*, 31:S33-S42 (1978). An imbalance in intestinal microflora population can eventually present gastro-intestinal disorders/conditions (*i.e.*, irritable bowel syndrome or ulcers).

Drugs have been produced that are efficient in the control and treatment of stress and impairment. Unfortunately, few, if any, of those drugs produce both an etiopathogenic action as well as symptomatological action.

Therefore, what is needed is a safe and effective method of stimulating immune responsiveness (*i.e.*, by restoring or enhancing T- and B-lymphocyte function) in the lymphatic system, in particular to stimulate growth in the thymus and spleen and to enhance villi length and goblet cell production in mucosae. What is also needed is a means for reducing stress. In doing so, lymphatic organ activity may be maintained and/or augmented.

However, to date, there is no effective treatment that will cause the thymus to reverse the process of involution and produce new T-lymphocytes. Nor has a successful method been provided to enhance splenic function and/or enhance mucosa protection against pathogens as well as treat stress. Further, there has been no disclosure to date regarding the use of a cysteamine compound for ensuring optimal lymphatic organ mass as well as treating stress.

Brief Summary of the Invention

The subject invention provides materials and methods for affecting biological immune systems in many different ways. In particular, the subject invention enables increased bioactivity in lymphatic organs. For example, by utilizing the methods of the invention, a patient can enhance the ability of mucosa to combat and/or prevent the occurrence of immunological diseases/disorders. In addition, methods of the invention can increase mass (or retard the deterioration in mass) of certain lymphatic organs (*i.e.*, thymus or spleen). Further, the invention is useful in the treatment of stress-related physiological responses; the alleviation of stress-related symptoms; as well as the prevention or delay in development of stress-related complications (*i.e.*, dampened immune function).

Specifically exemplified herein is the use of a cysteamine compound to restore, maintain, and/or improve the performance of a patient's lymphatic system. The use of a cysteamine compound can also independently or concurrently treat stress and stress-related symptoms and complications. With respect to the lymphatic system, a cysteamine compound augments immune response by: increasing or maintaining organ mass, which enhances both T- and B-cell bioactivity; increasing villi growth along mucosal linings;

and/or increasing goblet cell activity to enhance non-specific immune defenses against antigens.

With respect to stress, a cysteamine compound lowers cortisol levels in a patient. Under stress, the body releases neurotransmitters (*i.e.*, epinephrine, norepinephrine, serotonin) and cortisol to get the body back to a non-stressed state. In a chronic stress state, the neurotransmitters can become depleted and as a result, the lack of serotonin is directly related to poor mood and depression. Cortisol, however, does not get depleted and its continued presence in the body depresses mood. Long term exposure to cortisol leads to impaired memory, depressed immune function, central obesity, and development of chronic disease. Thus, administration of at least a cysteamine compound can treat stress-related physiological responses as well as treat and/or prevent stress-related symptoms and/or complications (*i.e.*, decrease risk of chronic disease like heart disease and obesity due to long-term exposure to cortisol).

In one embodiment, a cysteamine compound is administered to a patient either alone or concurrently with agent(s) known to treat stress and/or stress-related symptoms and/or complications.

In accordance with the subject invention, administration of a cysteamine compound to a patient prior to experiencing a stressful event can help protect the patient from experiencing physiological responses induced by stress, or at least ensure that physiological responses to stress occur to a lesser extent than would be observed in the absence of the cysteamine compound. The administration of a cysteamine compound may even be beneficial to the patient's subsequent abilities to withstand the adverse effects of subsequently encountered stresses. For example, patients administered at least a cysteamine compound can be preconditioned for improved resistance and reaction to subsequently encountered stress.

In another embodiment, a cysteamine compound is administered to prevent and/or delay the development of stress-related symptoms and complications in patients. For example, stress-related symptoms or complications such as diminished mental and physical performance (*i.e.*, chronic anxiety, nervous habits, insomnia, migraines, low back pain, nailbiting, skin picking, lack of sex-drive, loss of appetite, irrational behavior),

hypertension, irritable bowel syndrome (IBS), obesity (caused from stress eating), drug and alcohol abuse, hair loss, Chronic Fatigue Syndrome, heartburn, gastric reflux, asthma, allergies, dampened immune function (*i.e.*, chronic viral infections), breathing disorders, bruxism, premature aging, depression, hyperlipidemia, cardiovascular disease, and diabetes, can be reduced through consumption, according to the subject invention, of a cysteamine compound.

In yet another embodiment, a cysteamine compound is administered to a patient diagnosed with an immunological disorder and/or condition to treat the disorder/condition as well as prevent and/or decrease the severity of complications related to the disorder/condition. In a related embodiment, a cysteamine compound is administered in combination with other known agents that are used to treat immunological disorders/conditions (*i.e.*, autoimmune, inflammatory, proliferative and hyperproliferative diseases, cutaneous manifestations of immunologically mediated diseases).

Specifically exemplified herein is the use of a cysteamine compound to increase or maintain the mass of the thymus and/or spleen. Further, in a related embodiment, the use of a cysteamine compound increases villi length and goblet cell production in mucosa(e) in a patient to enhance immunological responsiveness. For example, common immunological disorders and/or conditions such as autoimmune disorders (*i.e.*, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, dermatomyositis, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Graves disease), immune deficiency (*i.e.*, AIDS), and multiple chemical sensitivity, can be treated through administration, according to the subject invention, of a cysteamine compound.

A therapeutically effective amount of a cysteamine compound for administration to a patient can be from about 0.1 mg to 3,000 mg/kg of body weight (BW). Preferably, a cysteamine compound is administered to an adult patient at about 50 mg to 1,500 mg per day. In a more preferred embodiment, about 200 mg to 900 mg of cysteamine hydrochloride is administered daily to an adult patient.

Brief Description of Drawings

Figure 1 shows a metabolic pathway of cysteamine.

Figure 2 shows cysteamine as a constituent of co-enzyme A.

5 **Figure 3** is a graphical illustration of cysteamine effect on IL-2 serum concentrations when administered in accordance with the subject invention.

Detailed Disclosure of the Invention

10 The subject invention provides materials and methods for treating stress and/or augmenting immune activity. Certain embodiments of the present invention are directed to the treatment and/or prevention of stress-related physiological responses; the alleviation of stress-related symptoms; as well as the prevention or delay in development of stress-related complications (*i.e.*, dampened immune function). Further embodiments of the invention include the treatment of patients diagnosed with immunological diseases/disorders or prevent the occurrence of such diseases/disorders in a patient.

15 As used herein, "immunological diseases/disorders" includes conditions associated with previous treatment with chemotherapeutic agents, radiation, immunosuppressive and anti-inflammatory drugs and dialysis; conditions such as severe combined immunodeficiency, congenital thymic aplasia, aplastic anemia, viral infections, chronic granulomatous disease and immune dysfunction associated with diabetes; 20 adverse reactions to bone marrow or organ transplantation such as graft-versus-host disease; physical findings such as rashes, fevers, and adverse reactions indicative of leukemias, lymphomas, inflammatory bowel disease or psoriasis. In addition, the term "immunological diseases/disorders" includes diseases classified as autoimmune in nature (see, Theofilopoulos, A., In: D. P. Stites, *et al.*, eds., Basic and Clinical Immunology, 25 Lange Medical Publications, Los Altos, Calif., 1988, which is incorporated in its entirety by reference).

30 The term "stress," as used herein, refer to the physical, chemical, and/or emotional factor that causes bodily or mental tension, which may be a factor in disease causation. A "stressful event" or "stressful situation," as used herein, refers to a

psychological and/or physical occurrence that causes a patient to be affected by stress. Examples of stressful events include, but are not limited to, experiencing and/or anticipating the following: pressure to perform at work, school, or in sports, threats of physical violence, money worries, arguments, family conflicts, divorce, bereavement, unemployment, moving from a house, and alcohol and/or drug abuse.

The term "symptom(s)" as used herein, refers to common signs or indications that a patient is suffering from a specific condition or disease. For example, stress-related symptoms contemplated herein include, but are not limited to, uncontrollable shaking; hyperventilation; vomiting; triggering of an asthma attack; periods of irritability or anger; apathy or depression; constant anxiety; irrational behavior; loss of appetite; comfort eating; lack of concentration; lack of sex-drive; increased smoking, drinking, or recreational drug-taking; excessive tiredness; skin problems; aches and pains resulting from tense muscles (including neckache, backache, and tension headaches); increased pain from arthritis and other conditions; heart palpitations; irregular menstruation cycles (for women); constipation or diarrhea; dizziness; fainting spells; nail biting; frequent crying; sensation of pins and needles; increased tendency to perspire; and difficulty sleeping.

As used herein, the term "complication(s)" refers to a pathological process or event occurring during a disease or condition that is not an essential part of the disease or condition; where it may result from the disease/condition or from independent causes. For example, stress-related complications refer to medical/clinical problems that occur more often in patients who suffer from excessive, prolonged stress. As contemplated herein, complications associated with stress include, without limitation, increased susceptibility to bacterial infections (*i.e.*, tuberculosis, group-A streptococcal diseases), gastrointestinal disorders (*i.e.*, stomach and duodenal ulcers, irritable bowel syndrome), cardiovascular diseases/disorders (*i.e.*, hypertension, atherosclerosis, myocardial infarction, arrhythmia), asthma, rheumatoid arthritis, thyroid over-activity, and dermatological conditions (*i.e.*, eczema, hives, psoriasis, or acne).

The term "patient," as used herein, describes an organism, including mammals, to which treatment with the compositions according to the present invention is provided.

Mammalian species that benefit from the disclosed methods of treatment include, but are not limited to, apes, chimpanzees, orangutans, humans, monkeys; and domesticated animals (*i.e.*, pets) such as dogs, cats, mice, rats, guinea pigs, and hamsters.

“Concurrent administration” and “concurrently administering,” as used herein, includes administering a compound or therapeutic method suitable for use with the methods of the invention. For example, for physical symptoms and/or complications that often accompany stress (*i.e.*, gastro-intestinal conditions), a cysteamine compound can be concurrently administered with methods and/or pharmaceuticals known to be useful in treating such symptom/complication (*i.e.*, antibiotics, acid blockers, antacids, proton pump inhibitors, cytoprotective agents, change in lifestyle such as cessation in smoking, *etc.*). In another example, a cysteamine compound can be concurrently administered with methods and/or pharmaceuticals known to be useful in treating immune deficiency disorders (*i.e.*, AIDS).

By way of example, a compound for use with a cysteamine compound of the invention can be provided in admixture with the cysteamine compound, such as in a pharmaceutical composition. Alternatively, the compound and cysteamine can be provided as separate compounds, such as, for example, separate pharmaceutical compositions administered consecutively, simultaneously, or at different times. Preferably, if the cysteamine compound and the known agent (or therapeutic method) for treating/preventing stress and stress-related symptoms/ complications are administered separately, they are not administered so distant in time from each other that the cysteamine compound and the known agent (or method) cannot interact.

As used herein, reference to a “cysteamine compound” includes cysteamine, the various cysteamine salts, which include pharmaceutically acceptable salts of a cysteamine compound, as well as prodrugs of cysteamine that can, for example, be readily metabolized in the body to produce cysteamine. Also included within the scope of the subject invention are analogs, derivatives, conjugates, and metabolites of cysteamine, which have the ability as described herein to treat stress and/or augment immune function. Various analogs, derivatives, conjugates, and metabolites of cysteamine are well known and readily used by those skilled in the art and include, for

example, compounds, compositions and methods of delivery as set forth in U.S. Patent Nos. 6,521,266; 6,468,522; 5,714,519; and 5,554,655.

As contemplated herein, a cysteamine compound includes pantothenic acid. Pantothenic acid is a naturally occurring vitamin that is converted in mammals to coenzyme A, a substance vital to many physiological reactions. Cysteamine is a component of coenzyme A, and increasing coenzyme A levels results in increased levels of circulating cysteamine. Alkali metal salts, such as magnesium phosphate tribasic and magnesium sulphite (Epsom salts), enhance formation of coenzyme A. Furthermore, breakdown of coenzyme A to cysteamine is enhanced by the presence of a reducing agent, such as citric acid. Thus, the combination of pantothenic acid and alkali metal salts results in increased coenzyme A production and, concomitantly, cysteamine.

The term "pharmaceutically acceptable salt," as used herein, refers to any salt of a cysteamine compound that is pharmaceutically acceptable and does not greatly reduce or inhibit the activity of the cysteamine compound. Suitable examples include acid addition salts, with an organic or inorganic acid such as acetate, tartrate, trifluoroacetate, lactate, maleate, fumarate, citrate, methane, sulfonate, sulfate, phosphate, nitrate, or chloride.

Accordingly, in one embodiment of the subject invention, the advantages of cysteamine, as set forth herein, can be achieved by promoting the endogenous production of cysteamine through natural metabolic process such as through the action of co-enzyme A or as a metabolite of cysteine (see Figures 1 and 2). This can be achieved by, for example, the administration of pantothenic acid.

The term "effective amount," as used herein, refers to the amount necessary to elicit the desired biological response. In one embodiment of the invention, the effective amount of a cysteamine compound is the amount necessary to treat/prevent stress and/or stress-related symptoms/complications. In another embodiment, an effective amount of a cysteamine compound is the amount necessary to prevent the deterioration of thymus mass. In a further embodiment, an effective amount of a cysteamine compound is that necessary to ameliorate the severity of symptoms and/or complications associated with stress or decreased/dysfunctional lymphatic activity. The amelioration in symptom and/or complication severity may be a 5%, 10%, 15%, 20%, 25% 30%, 35%, 40%, 45%,

50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% decrease in severity.

5 The compositions of the invention can be used in a variety of routes of administration, including, for example, orally-administrable forms such as tablets, capsules or the like, or via parenteral, intravenous, intramuscular, transdermal, buccal, subcutaneous, suppository, or other route. Such compositions are referred to herein generically as "pharmaceutical compositions." Typically, they can be in unit dosage form, namely, in physically discrete units suitable as unitary dosages for human consumption, each unit containing a predetermined quantity of active ingredient
10 calculated to produce the desired therapeutic effect in association with one or more pharmaceutically acceptable other ingredients, *i.e.*, diluent or carrier.

The cysteamine compounds of the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations are described in a number of sources, which are well known and readily available to those skilled in the art. For example, *Remington's Pharmaceutical Science* (Martin EW [1995] Easton Pennsylvania, Mack Publishing Company, 19th ed.) describes formulations that can be used in connection with the subject invention. Formulations suitable for parenteral administration include, for example, aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes, which render the
15 formulation isotonic with the blood of the intended recipient; and aqueous and nonaqueous sterile suspensions, which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the condition of the sterile liquid carrier, for example, water for
20 injections, prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powder, granules, tablets, *etc.* It should be understood that in addition to the ingredients particularly mentioned above, the formulations of the subject invention can include other agents conventional in the art having regard to the type of
25 formulation in question.

Administration of a cysteamine compound, in accordance with the subject invention, can be accomplished by any suitable method and technique presently or prospectively known to those skilled in the art. In a preferred embodiment, a cysteamine compound is formulated in a patentable and easily consumed oral formulation such as a pill, lozenge, tablet, gum, beverage, *etc.* In one embodiment, consumption of a cysteamine compound is taken at, prior to, or after, experiencing a stressful event. In another embodiment, a cysteamine compound is administered to a patient prior to, during, or after a decline in thymus and/or spleen mass.

Compositions of the invention comprise, as an active ingredient, an effective amount of the cysteamine and one or more non-toxic, pharmaceutically acceptable carrier or diluent. Examples of such carriers for use in the invention include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, sorbitol, inositol, xylitol, D-xylose, mannitol, powdered cellulose, microcrystalline cellulose, talc, colloidal silicon dioxide, calcium carbonate, magnesium carbonate, calcium phosphate, calcium aluminium silicate, aluminium hydroxide, sodium starch phosphate, lecithin, and equivalent carriers and diluents.

To provide for the administration of such dosages for the desired therapeutic treatment, compositions of the invention will typically comprise between about 0.1% and 99%, of the total composition including carrier or diluent. The dosage used can be varied based upon the age, weight, health, or the gender of the individual to be treated.

In certain embodiments, methods of the present invention are used for retarding the deterioration of and/or maintaining mass in the thymus and/or spleen of a patient to treat and/or prevent the development of immunological diseases/disorders including immune mediated cancers and hyperactive immune responses. Such immune mediated cancers may include lymphoreticular neoplasia, lymphoblastic leukemia, brain tumors, gastric tumors, plasmacytomas, multiple myeloma, leukemia, connective tissue tumors, solid tumors and lymphomas. Such hyperactive immune responses may include asthma/allergies and autoimmune diseases. Such allergies may include hay fever, atopic dermatitis, urticaria, perennial rhinitis, allergic conjunctivitis, pulmonary diseases, food

allergies, skin allergies, anaphylaxis (e.g., associated upon exposure to blood products) and pollinosis.

In other embodiments, methods of the present invention are used for preventing the deterioration of and/or maintaining the mass in the thymus and/or spleen of a patient to treat and/or prevent the development of autoimmune diseases including, without limitation, type 1 diabetes, conventional organ specific autoimmunity, neurological disease, rheumatic diseases/connective tissue disease, autoimmune cytopenias, and related autoimmune diseases. Conventional organ specific autoimmunity may include: thyroiditis (Graves+Hashimoto's), gastritis, adrenalitis (Addison's), ovaritis, primary biliary cirrhosis, myasthenia gravis, gonadal failure, hypoparathyroidism, alopecia, malabsorption syndrome, pernicious anemia, hepatitis, anti-receptor antibody diseases and vitiligo. Neurological diseases may include schizophrenia, Alzheimer's disease, depression, hypopituitarism, diabetes insipidus, sicca syndrome and multiple sclerosis. Such rheumatic diseases/connective tissue diseases may include rheumatoid arthritis, systemic lupus erythematosus (SLE) or Lupus, scleroderma, polymyositis, inflammatory bowel disease, dermatomyositis, ulcerative colitis, Crohn's disease, vasculitis, psoriatic arthritis, exfoliative psoriatic dermatitis, pemphigus vulgaris, Sjorgren's syndrome. Other autoimmune related diseases may include autoimmune uveoretinitis, glomerulonephritis, post, myocardial infarction cardiomy syndrome, pulmonary hemosiderosis, amyloidosis, sarcoidosis, aphthous stomatitis, and other immune related diseases, as presented herein and known in the related arts. See, e.g., Berkow *et al.*, eds, The Merck Manual, 16th edition, Merck and Co., Rahway, N.J., 1992, pages 303-364, 710-718, 1083, 1269, 1305-1377, 1338 1677-1684, and 2435-2438 which is incorporated herein in its entirety by reference.

Specifically exemplified herein is the use of cysteamine hydrochloride (and/or analogs, derivatives and prodrugs thereof) to treat and/or prevent the occurrence of an immunological disease/disorder in a patient.

In one embodiment, the dosage of cysteamine administered to a patient to elicit a desired response is about 0.1 mg to about 3,000 mg per day. The desired response can include (1) prevention of bodily and/or mental tension as a response to stress; (2) a

reduction in the severity, duration, or intensity of bodily and/or mental tension as well as symptoms associated with stress; and (3) prevention, delay, or reduction in the severity, duration, or intensity of complications related to stress. Preferably, cysteamine hydrochloride is administered daily at about 50 mg to 1,000 mg to elicit a desired response. In a more preferred embodiment, the dosage of cysteamine hydrochloride administered to a patient to elicit a desired response is about 200 mg to 900 mg per day.

Following is an example that illustrates a procedure for practicing the invention.

This example should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1—Administration of Cysteamine Compound in Treating Stress

An experiment was conducted on eight castrated adult goats, which were randomly divided into control group (n=4) and treatment group (TG, n=4); housed separately; and fed with the same nutrient level. The TG was treated orally with a cysteamine compound (the cysteamine compound is preferably cysteamine hydrochloride, where a dose of 45mg/kg of body weight was administered, with 30 % of the 45mg/kg dosage comprising the cysteamine compound) provided by Shanghai Walcom Bio-Chem Ltd). Both groups were subjected to rumen operation and duodenum operation.

This experiment was conducted in four phases: (a) Roughage phase pre-operation: from day 14 to day 11 before the operation, both groups of goats were fed with roughage (dried peanut stalk) and water; (b) Concentrate phase pre-operation: day 10 to day 1 before the operation (in total 10 days), both groups were fed with roughage and concentrate (50g/head), and the TG was also treated with a cysteamine compound (using dosages described above) at the same time; (c) Rumen operation phase: after completion of the concentrate phase pre-operation, the rumen operation was performed to affix a fistula on the rumen, which was followed by 14 days of recovery; (d) Duodenum operation phase: 14 days after the rumen operation, a second operation was performed to affix a fistula on the duodenum, following which the goats were allowed to have 13 days

of recovery to complete this experiment. The feeding diet during the operation was same as that of concentrate phase per-operation.

While conducting the experiment, blood samples were periodically collected. In general, blood was collected via the neck vein before morning feeding. Part of the blood from each sample was stored in tubes containing heparin for anti-coagulation. The remaining part of each blood sample was centrifuged and then stored the serum at -20 C. Blood samples were collected at the following times: (a) Day 3 of the Roughage phase pre-operation; (b) Day 10 of the Concentrate phase (one day before the operation, B1); (c) 8 days after the 1st operation (rumen operation); and (d) 4 days and 13 days after the 2nd operation (duodenum operation).

Serum IL-2, cortisol concentration and lymphatic transformation testing were also performed during the experiment. Radio-immuno assay (RIA) was used to test the serum IL-2 and cortisol concentration with respect to the suggested protocol. To perform lymphatic cells transformation test, the blood samples from both groups were treated as follows: 3 tubes/sample, with blood sample 100ul/tube for PHA- (PHA-: without PHA) and 3 tubes/sample for PHA+ (PHA+: each tube added with 50 ul PHA diluted solution); cells in both PHA- and PHA+ were cultured for total 72 hours. After 48 hours of cell culture, 1 uL ³H-TdR was added to each tube with and mixed with cells and incubated further for 24 hours. At the completion of the culturing process, the cells were lysed. The lysate from both PHA- and PHA+ tubes were transferred to scintillation bottles, dried at 80° C, then added with 5 ml scintillation solution. The solutions were stored overnight and tested for cpm. SI index implies the rate of lymphatic cells transformation induced by lectin, $SI = \text{cpm(PHA+)}/\text{cpm(PHA-)}$.

IL-2 and cortisol testing kits were purchased from Beijing Northern Biotechnology Research Institute. To prepare RPMI-1640 cell culture medium, RPMI-1640 powder (GIBCO) was added with distilled water and filtered, and 20% Fetal Bovine Serum (Hangzhou Seasons Green Company), Penicillin (100U/ml) as well as Streptomycin (100U/ml) was added. 2 ml culture medium solution was then added to each tube. In addition, diluted PHA (Shanghai Eva technology company), [Methy-³H] Thymidine with radioactivity 1 mci/m (China Science Institute Nuclear research center), and Scintillation

solution: PPO (2,5, Diphenyloxazole,) 5g (Beckman) POPOP(1,4-bis [5-phenyloxazolyl] benzene) 0.3 g (The First Shangahi Testing Kit Ltd.) Dimethyl benzene : 800 mL; 100% ethanol: 200 ml were added to each tube.

Certain steps in the experiment required the following equipment: CO₂ incubator (USA REVCO Ltd.), LDR4-8.4 C Centrifuge (Beijing Medical Centrifuge Ltd.), and SN-6904 Scintillation counter (Shanghai Nuclear Research Center).

All data from the experiment (see Table 1) were expressed in mean \pm SE and analyzed by Excel software for t-test analysis, where $P < 0.05$ implies significant difference, and $0.05 < P < 0.15$ implies changes. The symbol “§” in Table 1 denotes TG treated with Cysteamine. The symbol “*” in Table 1 denotes differences between groups with $P < 0.05$; and the symbol “#” denotes differences between groups with $0.05 < P < 0.15$. The symbol “^{ab}” in Table 1 denotes differences between periods within the same group with $P < 0.05$; whereas the symbol “^{AB}” in Table 1 denotes differences between periods within the same group with $0.05 < P < 0.15$.

Table 1—Cysteamine effect on IL-2 serum concentration in pre-, post-operation periods					
Group	Pre-operation		After 1 st Operation (ug/l)	After 2 nd Operation	
(n=4)	Roughage phase	Concentrate Phase	Day 8 [§]	Day 4 [§]	Day 13 [§]
Control	1.15 \pm 0.17	0.85 \pm 0.1 ^{aA}	0.71 \pm 0.08 ^B	0.52 \pm 0.12 ^b	0.59 \pm 0.11
Treatment	0.97 \pm 0.31	1.02 \pm 0.22 [#]	1.29 \pm 0.17 ^{*A}	0.92 \pm 0.09 ^{*B}	1.15 \pm 0.39

IL-2 concentration levels for each group taken at various times during the experiment are illustrated in Figure 3. As compared to pre-operation IL-2 concentration, post-surgery IL-2 concentrations are lower in the control group. In particular, the lowering effect was observed in the control group after the 1st surgery ($p=0.14$), and with a significant lowering effect after the 2nd surgery (0.85 ± 0.1 vs $0.52 \pm 0.22 \mu\text{g l}^{-1}$), $P < 0.05$.

In contrast, the IL-2 concentration in TG showed no significant difference between pre- and post-operation.

Before treatment with a cysteamine compound (in Roughage phase), serum IL-2 concentration levels between the control group and TG were not significantly different. In the Concentrate phase before the first operation, the IL-2 concentration levels in TG (0.85 ± 0.1 vs $1.02 \pm 0.22 \text{ ug l}^{-1}$) after treatment with a cysteamine compound were increased, but not significantly when compared with that of the control group ($P=0.11$). After the first operation, TG IL-2 concentration levels were higher than the control group by 80-90% (0.71 ± 0.08 vs $1.29 \pm 0.17 \text{ ug l}^{-1}$, 0.52 ± 0.12 vs $0.92 \pm 0.09 \text{ ug l}^{-1}$), which is a significant difference ($P<0.05$). After 13 days from the 2nd operation, the IL-2 concentration levels no longer fluctuated and the difference in IL-2 concentration levels between the two groups had disappeared.

In the Roughage phase pre-operation, there was no difference between the two groups in lymphatic cells transformation rate (44.71 ± 4.83 vs 45.91 ± 3.543). But in the Concentrate phase, the TG treated with a cysteamine compound increased in lymphatic cells transformation rate (93.18 ± 8.91 vs 129.1 ± 18.58), in which the difference was not significant when compared with the control group ($P=0.14$).

Both surgical operations caused the control group and the TG lymphatic cells transformation rate to decrease ($P<0.05$), where the degree of decrease in the TG was significantly smaller than that of the control group ($P<0.05$). Four days after the 2nd/duodenum operation, the lymphatic transformation rate of the control group decreased down to 10% of the rate before the operation, while the rate of TG lymphatic cell transformation had increased by 4 fold ($P<0.05$) when compared to the rate of the control group. In the following days, the lymphatic transformation rate started to recover (control group $P<0.05$) and the difference between the two groups disappeared ($P>0.05$).

The cortisol concentrations of for each group taken at various times during the experiment are provided in Table 2 below. Cortisol concentrations of the two groups before the operation were substantially similar (20.44 ± 4.52 for the control group versus $20.75 \pm 9.93 \text{ ug l}^{-1}$ for the TG). Changes in cortisol concentration levels in the TG before and after

the 1st operation were slight. In contrast, cortisol concentration levels in the control group after four days from the 2nd operation increased ($P=0.08$). In some instances, the cortisol concentration levels in the control group reached levels higher than the TG ($P=0.11$). The symbol “§” in Table 2 designates TG treated with Cysteamine. The symbol “*” in Table 2 designates a difference in cortisol concentration levels between groups with $P<0.05$. The symbol “^{ab}” designates a difference in cortisol concentration levels between periods within the same group with $P<0.05$. The symbol “#” designates a difference in cortisol concentration levels between periods within the same group with $0.05<P<0.15$.

Table 2—Cysteamine effect on cortisol serum concentration in pre-, post-operation periods					
Group	Pre-operation (ng/ml)		After 1 st operation (ug/l)	After 2 nd operation (ug/l)	
(n=4)	Roughage phase	Concentrate phase [§]	Day 8 [§]	Day 4 [§]	Day 8 [§]
Control	28.61±4.5	20.44±4.52 ^a	26.65±10.51 ^a	32.31±3.29	24.03±5.13
Treatment	23.3±3.62	20.75±9.93	20.62±5	19.66±5.83 #	21.91±10.78

Example 2—Administration of Cysteamine Compound and Immune Response in Murine Model

Male C57BL/6N mice were used in Example 2, 28 mice in total. The 28 mice were used for pretest for 7 days before the treatment began. Two groups of 14 mice were then created. As illustrated in Table 3, 12 mice from group 1 were orally administered a cysteamine compound, 27% (w/w) cysteamine hydrochloride, at a dosage of 40 mg/kg or 80 mg/kg of body weight. Each group contained six replicates and each replicate contained 8 mice. The treatment period was for 30 days.

Table 3—Experimental Model	
Control	Saline
Treatment 1	Cysteamine hydrochloride-40mg/kg BW
Treatment 2	Cysteamine hydrochloride-80mg/kg BW

Lymphocyte transformation rate in plasma, white blood cell (WBC) count, natural killer cell activity, Plasma IL-2 (Kit provided by Jingmei Biotech) and IL-6 (Kit provided by Bender MedSystems) measurements, and antibody forming cell count were performed according to methods known to the skilled artisan (see "Medical Immunology Experiment," Publisher: People Hygiene, Published in 1999 in China, Editor: Xi Chuan Ping). Five days before the end of the treatment, 12 mice from each group (each replicate for 2 mice) were immunized with 0.5 ml of 2% sheep RBC (equivalent to 2×10^8 cells per ml) for testing spleen B-cells. The relative weights of spleen and thymus to body weight (mg/ 100g BW) were also measured. All statistical analyses were performed on ANOVA.

After conducting all tests and analyses, the relative weight of certain immune organs, namely the thymus and spleen, were measured, as illustrated in Table 4.

Table 4—Measurement of Organ Weight (mg/100g of body weight)			
Organ	Control	Treatment 1	Treatment 2
Thymus	534±5.04 ^C	549±1.89 ^B	567±7.18 ^A
Spleen	290±6.33	298±5.03	296±7.50

Note: Different superscript means statistically significant difference

"A" and "B" or "B" and "C" means $P < 0.05$

"A" and "C" means $P < 0.01$

The WBC count, lymphocyte transformation rate (specifically in the spleen), antibody forming cell, and natural killer cell killing rate (based on the killing rate of K562 cells by natural killer cell) were measured and analyzed, as illustrated in Tables 4 and 5.

Table 5—Analyses of Treatments			
Item	Control	Treatment 1	Treatment 2
WBC Count ($10^9/L$)	6.78 ± 0.54	7.12 ± 0.65	7.53 ± 0.55
Lymphocyte Transformation (SI Value, Stimulation Index)	1.10 ± 0.05^B	1.15 ± 0.02^B	1.24 ± 0.05^A
Antibody Forming Cell (OD, Optical Density)	1.44 ± 0.23^A	1.48 ± 0.19^A	0.91 ± 0.51^C
NK Killing Rate (%)	90.29 ± 2.24	92.19 ± 2.20	93.60 ± 2.21

Table 6—Plasma IL-2 and IL-6 Measurements			
Item	Control	Treatment 1	Treatment 2
IL-2 (pg/ml)	6.05 ± 0.44	5.88 ± 0.53	5.76 ± 0.50
IL-6 (pg/ml)	247.83 ± 49.40	226.20 ± 37.93	247.00 ± 51.76

Lymphocyte transformation (or SI Value) is provided using CPM (Count per minute) of PHA containing tube / CPM (Count per minute) of tube without PHA. PHA-
 5 Phytohemagglutinin can stimulate inactive T-cell to convert to parental cell, which will eventually convert to active T-cell. In this regards, the stimulating index reflects the amount of inactivate T-cell available for turning into active T-cell. Thus, with a higher index, more inactive T-cells are present.

10 All patents, patent applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

15 It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

Abstract

The subject invention provides materials and methods for treating stress and/or augmenting immune response. More specifically, the present invention provides methods for the treatment and/or prevention of stress-related physiological responses; the alleviation of stress-related symptoms; as well as the prevention or delay in development of stress-related complications. The present invention further provides biologically-active compounds that can cause the thymus and spleen to increase in size and cause an increase in villi length and goblet cell production in mucosae. Specifically exemplified herein is the use of a cysteamine compound to modulate immune responsiveness and/or treat stress.

Cysteamine – Constituent of Co-enzyme A




FIG. 1

Metabolic Pathway of Cysteamine





FIG. 2



Note: Difference between groups *: $P < 0.05$, #: $0.05 < P < 0.15$. Difference between periods within same group ^{ab/AB}: $P < 0.05$.

FIG. 3